BRAF抑制剂治疗非小细胞肺癌的进展

Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors

近年来,靶向药物在非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗中占据着举足轻重的地位,针对表皮生长因子受体(epidermal growth factor receptor,EGFR)的靶向药物已在临床上广泛应用,具有里程碑意义。BRAF抑制剂是针对鼠类肉瘤病毒癌基因同源物B1(V-raf murine sarcoma viral oncogene homolog B1,BRAF)基因突变为靶点的靶向药物,对特定优势人群有明显的临床疗效,且毒副作用小,患者易耐受。近期发现,与其他靶向药物一样,BRAF抑制剂也存在耐药现象,其耐药机制正在研究中。本文就BRAF抑制剂的作用机制、临床应用、不良反应及耐药问题进行综述。

In recent years, targeted drugs occupy a pivotal position in the treatment of non-small cell lung cancer（NSCLC）, drugs targeting epidermal growth factor receptor（EGFR） has been widely used in clinical practice, it is of milestone significance. V-raf murine sarcoma viral oncogene homolog B1（BRAF） inhibitors targeted at BRAF gene have obviously clinical efficacy to specific advantages populations with little side-effect, and be well tolerated. It is discovered recently that drug resistance also exists in BRAF inhibitors like other targeted drugs, the mechanism of drug resistance is being studied. In this paper, a review were performed in the mechanism, clinical application, adverse reactions and the drug resistance of BRAF inhibitors.